Tuesday, May 04, 2021 2:52:07 PM
appointment today
suggests they feel pretty confident about how this phase 3 test will turn out, set to commence 'soon'.
best
who
suggests they feel pretty confident about how this phase 3 test will turn out, set to commence 'soon'.
best
who
“Any state, any entity, any ideology that fails to recognize the worth, the dignity, the rights of man, that state is obsolete”
? Rod Serling
Recent VTGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:52:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:51:49 PM
- Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer • Business Wire • 05/19/2026 12:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:26:37 PM
- Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:44:41 AM
- Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder • Business Wire • 05/12/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:30:08 PM
- Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder • Business Wire • 05/08/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:13:15 PM
- Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop • PR Newswire (US) • 04/28/2026 01:00:00 PM
- Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause • Business Wire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 09:27:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:43:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:41:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:40:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:33:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:16:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 08:45:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:10:38 PM
- Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN • PR Newswire (US) • 03/16/2026 06:38:00 AM
- Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN • PR Newswire (US) • 03/12/2026 07:29:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2026 11:02:20 AM
- Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN) • PR Newswire (US) • 03/10/2026 01:00:00 PM
